Monte Rosa Therapeutics (GLUE) Return on Sales (2024 - 2026)

Monte Rosa Therapeutics' Return on Sales history runs 3 years deep, the most recent figure standing at 0.1% for Q1 2026.

• In Q1 2026, Return on Sales fell 11.0% year-over-year to 0.1%; the TTM figure through Mar 2026 stood at 0.26% (down 26.0% YoY), while the FY2025 annual figure was 0.0%, up 1.0% from the prior year.
• Return on Sales was 0.1% for Q1 2026 at Monte Rosa Therapeutics, up from 0.11% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.01% in Q1 2025 to a low of 0.3% in Q1 2024.
• Historically, Return on Sales has averaged 0.07% across 3 years, with a median of 0.03% in 2024.
• Biggest YoY gain for Return on Sales was 31 bps in 2025; the steepest drop was 11 bps in 2025.
• A 3-year view of Return on Sales shows it stood at 0.0% in 2024, then plunged by 4886 bps to 0.11% in 2025, then grew by 2 bps to 0.1% in 2026.
• The last three Return on Sales figures came in at 0.1% (Q1 2026), 0.11% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.